Loading…

Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats

Highlights • Fasciola hepatica in an important animal and human pathogen. • First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model. • 51.0% immune protection conferred.

Saved in:
Bibliographic Details
Published in:Vaccine 2017-01, Vol.35 (4), p.663-671
Main Authors: Henker, Luan C, Schwertz, Claiton I, Lucca, Neuber J, Piva, Manoela M, Prior, Keila C, Baska, Piotr, Norbury, Luke, Januszkiewicz, Kamil, Dezen, Diogenes, Duarte, Marta M.M.F, Moresco, Rafael N, Bertagnolli da Rosa, Liana, Mendes, Ricardo E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Fasciola hepatica in an important animal and human pathogen. • First experimental trial evaluating Fasciola hepatica MRLC antigen in a rodent model. • 51.0% immune protection conferred.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2016.11.092